Atezolizumab with cabozantinib for treating hormone-relapsed metastatic prostate cancer after 1 therapy [ID6203]
Discontinued
Reference number: GID-TA11163
Following the changes to remove technical engagement as standard from appraisal timelines, the timelines for the appraisal of Atezolizumab with cabozantinib for treating hormone-relapsed metastatic prostate cancer after 1 therapy have been revised. It is anticipated that the appraisal will begin in early-November 2023 when we will write to you about how you can get involved.